Justin George
Vascular Surgery · New York, NYNPI 1629462544
Payments from drug & device makers
Across 519 payments — averaging $254.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$47K
- Medtronic$25K
- Bard Peripheral Vascular, Inc.$22K
- Endologix LLC$12K
- Bolton Medical Inc$6K
- Wilson Cook Medical Incorporated$3K
- plus $18K from 30 others
What the payments were for
- Consulting fees$33,77526%
- Speaking & faculty fees$60,60446%
- Travel & lodging$10,2018%
- Food & beverage$26,67220%
- Other$7711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 99 | $47,115 |
| Medtronic | 85 | $25,015 |
| Bard Peripheral Vascular, Inc. | 12 | $22,298 |
| Endologix LLC | 37 | $11,666 |
| Bolton Medical Inc | 27 | $5,868 |
| Wilson Cook Medical Incorporated | 1 | $2,550 |
| Cook Incorporated | 1 | $2,450 |
| Abbott | 20 | $2,360 |
| Cook Medical LLC | 52 | $2,053 |
| Silk Road Medical, Inc. | 18 | $1,796 |
| Boston Scientific | 55 | $1,680 |
| Mimedx Group, Inc. | 12 | $1,391 |
| Integra Lifesciences Corporation | 5 | $845 |
| Shockwave Medical, Inc | 5 | $828 |
| Tactile Systems Technology Inc | 27 | $771 |
| W. L. Gore & Associates, Inc. | 11 | $618 |
| Argon Medical Devices, Inc. | 2 | $450 |
| Inari Medical, Inc. | 6 | $390 |
| Stryker | 2 | $299 |
| Smith+Nephew | 17 | $278 |
| Kerecis Limited | 3 | $209 |
| Terumo Medical Corporation | 2 | $201 |
| Cardiovascular Systems Inc. | 3 | $185 |
| Imperative Care, Inc | 2 | $178 |
| Philips North America LLC | 1 | $89 |
| Urgo Medical North America, LLC | 1 | $85 |
| Artivion, Inc. | 1 | $67 |
| Solventum Corporation | 2 | $53 |
| Johnson & Johnson | 1 | $43 |
| Lemaitre Vascular, Inc. | 2 | $40 |
| Convatec Inc. | 1 | $32 |
| Venturemed Group, Inc. | 1 | $30 |
| Laminate Medical Technologies Inc. | 1 | $29 |
| Cagent Vascular Inc | 2 | $26 |
| Advanced Oxygen Therapy Inc. | 1 | $20 |
| Teleflex LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$29,714
- HawkOne$13,372
- RUBY Coil$10,703
- Alto Abdominal Stent Graft System$6,742
- Zilver PTX$5,351
- Benchmark$4,800
- AFX2 Bifurcated Endograft System$4,297
- TREO ABDOMINAL STENT-GRAFT SYSTEM$3,294
- ENDURANT IIS$3,179
- ESPRIT$1,929
- RotarexS 6 F x 135 cm$1,616
- ENROUTE Transcarotid Stent$1,449
- ENROUTE Transcarotid Neuroprotection System$1,449
- RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM$1,199
- Grafts$903
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$778
- ACell$771
- ELUVIA$639
- Valiant Captivia$578
- Kerecis Omega3 Marigen$472
How this compares
$132,022 in reported general payments places this provider in the 90th percentile of 405 vascular surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $26,355 |
| SantylCollagenase Clostridium Hist. | 26 | $24,936 |
| ClopidogrelClopidogrel Bisulfate | 19 | $268 |
| Gabapentin | 21 | $123 |
| Oxycodone Hcl | 13 | $19 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $278 | $24,93626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 405 vascular surgery providers in New York.
Other vascular surgery in New York
- Gary GelbfishNew York$1.9M
- John LantisNew York$1.4M
- Brian DerubertisNew York$1M
- Thomas MaldonadoNew York$1M
- James McKinseyNew York$750K
- Peter FariesNew York$639K
- Virendra PatelNew York$590K
- Rami TadrosNew York$351K
- Ajit RaoNew York$329K
- Todd BerlandNew York$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.